Advertisement


Juliet Elizabeth Wolford, MD, on Ovarian Cancer: The Cost of Care

2018 ASCO Annual Meeting

Advertisement

Juliet Elizabeth Wolford, MD, of the University of California, Irvine, discusses the cost-effectiveness of various types of maintenance therapy in advanced ovarian cancer: paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab (Abstract 5508).



Related Videos

Issues in Oncology
Immunotherapy

Lee S. Schwartzberg, MD, on Using Immunotherapy in the Community Setting: 2018 Update on an ACCC Program

Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.

Lymphoma
Immunotherapy

Laurie Helen Sehn, MD, MPH, on FL and DLBCL: Results From a Treatment Trial

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).

Gynecologic Cancers

Ursula A. Matulonis, MD, and Daniel J. Margul, MD, PhD, on Cervical Cancer and Minimally Invasive Surgery

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Daniel J. Margul, MD, PhD, of Northwestern University, discuss the outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer (Abstract 5502).

Skin Cancer
Immunotherapy

Danny Rischin, MD, on Squamous Cell Carcinoma: Treatment Trial Results

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase II study findings on cemiplimab, a human monoclonal anti–PD-1 antibody, in patients with metastatic cutaneous squamous cell carcinoma (Abstract 9519).

Kidney Cancer
Immunotherapy

David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (Abstract 4500).

Advertisement

Advertisement




Advertisement